Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal–bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study
Authors' conclusion
FRC therapies such as iGlarLixi represent an appropriate treatment option when intensifying basal insulin therapy in ethnic minority older adults with T2D.
Study context
- Population
- African American, Asian and Hispanic adults with T2D aged ≥65 years on basal insulin newly initiating iGlarLixi, basal-bolus or premixed insulin (7/1/2019–12/30/2021), Medicare beneficiaries
- Exposure
- iGlarLixi vs basal-bolus insulin vs premixed insulin
- Outcome
- Treatment persistence
- Follow-up
- Up to 12 months
Methodological detailspropensity score matched, Medicare claims data, multivariable regression
- Propensity score matched
- Medicare claims data
- Multivariable regression
Main finding
As reported in the abstract
Adjusted p < 0.0001
Observational data: associations, not effects.
Further findings
Treatment adherence · overall population
Treatment persistence, ethnic subgroups
- Numerically higher with iGlarLixi in all ethnic subgroups
Treatment adherence
- Numerically higher with iGlarLixi in overall population and all subgroups
All-cause and diabetes-related hospitalisation and ED visit event rates
- Lower with iGlarLixi vs basal-bolus or premixed insulin overall and in all subgroups except hospitalisations in Hispanics
Safety
Hypoglycaemia event rates · overall population
Hypoglycaemia event rates
- Numerically lower with iGlarLixi overall and in all subgroups except Asians receiving basal-bolus insulin
Original publication
Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal–bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study. Diabetes Obes Metab. Published 27 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →